首页> 美国卫生研究院文献>Infection and Immunity >Randomized Double-Blind Placebo-Controlled Multicentered Trialof the Efficacy of a Single Dose of Live Oral Cholera Vaccine CVD103-HgR in Preventing Cholera following Challenge with Vibriocholerae O1 El Tor Inaba Three Months after Vaccination
【2h】

Randomized Double-Blind Placebo-Controlled Multicentered Trialof the Efficacy of a Single Dose of Live Oral Cholera Vaccine CVD103-HgR in Preventing Cholera following Challenge with Vibriocholerae O1 El Tor Inaba Three Months after Vaccination

机译:随机双盲安慰剂对照多中心试验口服活霍乱疫苗CVD的疗效分析103-HgR预防弧菌引起的霍乱接种疫苗三个月后爆发霍乱弧菌O1 El Tor Inaba

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CVD 103-HgR is a live oral cholera vaccine strain constructed by deleting 94% of the gene for the enzymatically active A subunit of cholera toxin from classical Inaba Vibrio cholerae O1 569B; the strain also contains a mercury resistance gene as an identifying marker. This vaccine was well tolerated and immunogenic in double-blind, controlled studies and was protective in open-label studies of volunteers challenged with V. cholerae O1. A randomized, double-blind, placebo-controlled, multicenter study of vaccine efficacy was designed to test longer-term protection of CVD 103-HgR against moderate and severe El Tor cholera in U.S. volunteers. A total of 85 volunteers (50 at the University of Maryland and 35 at Children's Hospital Medical Center/University of Cincinnati) were recruited for vaccination and challenge with wild-type V. cholerae El Tor Inaba. Volunteers were randomized in a double-blind manner to receive, with buffer, a single oral dose of either CVD 103-HgR (2 × 108 to 8 × 108 CFU) or placebo (killed E.coli K-12). About 3 months after immunization, 51 of thesevolunteers were orally challenged with 105 CFU ofvirulent V. cholerae O1 El Tor Inaba strain N16961,prepared from a standardized frozen inoculum. Ninety-onepercent of the vaccinees had a ≥4-fold rise in serum vibriocidalantibodies after vaccination. After challenge, 9 (39%) of the 23placebo recipients and 1 (4%) of the 28 vaccinees had moderate orsevere diarrhea (≥3-liter diarrheal stool) (P <0.01; protective efficacy, 91%). A total of 21 (91%) of 23 placeborecipients and 5 (18%) of 28 vaccinees had any diarrhea(P < 0.001; protective efficacy, 80%). Peak stoolV. cholerae excretion among placebo recipients was 1.1× 107 CFU/g and among vaccinees was 4.9 ×102 CFU/g (P < 0.001). This vaccine couldtherefore be a safe and effective tool to prevent cholera intravelers.
机译:CVD 103-HgR是一种活的口服霍乱疫苗株,它是从经典的Inaba霍乱弧菌O1 569B中删除了94%的酶促霍乱毒素A亚基的基因而构建的;该菌株还含有抗汞基因作为鉴定标记。该疫苗在双盲对照研究中具有良好的耐受性和免疫原性,并且在霍乱弧菌O1攻击的志愿者的开放标签研究中具有保护性。一项针对疫苗功效的随机,双盲,安慰剂对照多中心研究旨在测试CVD 103-HgR在美国志愿者中针对中度和重度El Tor霍乱的长期保护作用。总共招募了85名志愿者(马里兰大学50名,辛辛那提大学儿童医院医学中心35名)进行了野生型霍乱弧菌El Tor Inaba的疫苗接种和攻击。以双盲方式将志愿者随机分配,以单剂量口服CVD 103-HgR(2×10 8 至8×10 8 CFU) )或安慰剂(杀死的E.大肠杆菌K-12)。免疫后约3个月,其中51个月用10 5 CFU对志愿者进行口服挑战强毒霍乱弧菌O1 El Tor Inaba株N16961,由标准的冷冻接种物制备。九十一的被接种者中有百分之四倍的血清杀弧菌疫苗接种后的抗体。挑战之后,23人中有9人(39%)安慰剂接受者和28种疫苗中的1种(4%)患有中度或中度严重腹泻(≥3升腹泻大便)(P <0.01;防护功效,占91%)。总共23项安慰剂中有21项(91%)疫苗接种者和28种疫苗中的5种(18%)有腹泻(P <0.001;保护效力,80%)。高峰凳安慰剂接受者的霍乱弧菌排泄为1.1×10 7 CFU / g,被疫苗接种者为4.9×10 2 CFU / g(P <0.001)。这种疫苗可以因此是预防霍乱的安全有效工具旅行者。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号